布格替尼治疗克唑替尼耐药ALK+非小细胞肺癌:ALTA二期研究2年随访的全身与颅内结局
本研究报告ALTA二期随机研究2年随访数据,评估布格替尼在克唑替尼耐药ALK阳性非小细胞肺癌中的疗效。222例患者随机接受90mg每日一次(A组)或180mg每日一次(7天导入90mg,B组)。结果显示B组在无进展生存期、颅内客观缓解率和颅内缓解持续时间方面均优于A组,且未观察到新的安全性信号。
要点
- 布格替尼180mg组中位无进展生存期16.7个月,优于90mg组的9.2个月。
- 180mg组颅内客观缓解率67%,颅内缓解持续时间16.6个月。
- 靶病灶缩小程度越深,无进展生存期越长。
核心结论
- 布格替尼180mg每日一次(7天导入90mg)在克唑替尼耐药ALK阳性非小细胞肺癌中持续显示稳健的无进展生存期、长颅内无进展生存期和颅内缓解持续时间,以及高颅内客观缓解率。
- 缓解深度可能是未来靶向治疗试验中需要捕捉的重要终点。
研究设计与样本
- 二期随机研究,222例克唑替尼耐药ALK阳性非小细胞肺癌患者按1:1随机接受布格替尼90mg每日一次(A组,112例)或180mg每日一次(7天导入90mg,B组,110例)。
- 分层因素为中枢神经系统转移状态和克唑替尼最佳疗效。
- 主要终点为研究者评估的确认客观缓解率(RECIST 1.1)。
- 次要终点包括独立评审委员会评估的无进展生存期、颅内无进展生存期和总生存期。
主要发现
- 分析时59例(27%)仍在接受布格替尼治疗,中位随访时间A组19.6个月,B组24.3个月。
- 基线时A组71%、B组67%的患者有脑病灶。
- 研究者评估的确认客观缓解率A组46%,B组56%。
- 独立评审委员会评估的中位无进展生存期A组9.2个月(95%CI 7.4-12.8),B组16.7个月(95%CI 11.6-21.4)。
- 中位总生存期A组29.5个月(95%CI 18.2-未达到),B组34.1个月(95%CI 27.7-未达到)。
关键数值与推荐
- 基线有可测量脑病灶的患者中,独立评审委员会确认的颅内客观缓解率A组50%(13/26),B组67%(12/18)。
- 中位颅内缓解持续时间A组9.4个月,B组16.6个月。
- 独立评审委员会评估的颅内无进展生存期A组12.8个月,B组18.4个月。
- 两组合并分析,靶病灶缩小0%、1%-25%、26%-50%、51%-75%、76%-100%的患者中位无进展生存期分别为1.9、5.5、11.1、16.7、15.6个月。
- 更长随访未观察到新的安全性发现。
临床怎么用
- 对于克唑替尼耐药的ALK阳性非小细胞肺癌,布格替尼180mg每日一次(7天导入90mg)方案显示更优的无进展生存期和颅内疗效。
- 基线有脑病灶的患者可从布格替尼治疗中获得较高的颅内客观缓解率和持久的颅内缓解。
- 治疗中靶病灶缩小程度与无进展生存期相关,深度缓解可能作为疗效评估的参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We report updated data from a phase 2 randomized study evaluating brigatinib in crizotinib-refractory anaplastic lymphoma kinase-positive NSCLC. METHODS: Patients were randomized 1:1 to take either oral brigatinib 90 mg once daily (arm A) or 180 mg once daily with a 7-day lead-in at 90 mg (arm B), stratified by central nervous system (CNS) metastases and best response to crizotinib. The primary end point was investigator-assessed confirmed objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1. Secondary end points included independent review committee (IRC)-assessed progression-free survival (PFS), intracranial PFS (iPFS), and overall survival (OS). Exploratory analyses included CNS versus ex-CNS target lesion response and correlation of depth of response with PFS and OS. RESULTS: Among 222 randomized patients (112 and 110 in arms A and B, respectively), 59 (27%) remained on brigatinib at analysis (median follow-up: 19.6 versus 24.3 months). At baseline, 71% and 67% had brain lesions among A and B arms, respectively. Investigator-assessed confirmed objective response rate was 46% versus 56%. Median IRC-assessed PFS was 9.2 months (95% confidence interval: 7.4-12.8) versus 16.7 months (11.6-21.4). Median OS was 29.5 months (18.2-not reached) versus 34.1 months (27.7-not reached). IRC-confirmed intracranial objective response rate in patients with measurable baseline brain lesions was 50% (13 of 26) versus 67% (12 of 18); median duration of intracranial response was 9.4 versus 16.6 months. IRC-assessed iPFS was 12.8 versus 18.4 months. Across arms, median IRC-assessed PFS was 1.9, 5.5, 11.1, 16.7, and 15.6 months for patients with no, 1%-25%, 26%-50%, 51%-75%, and 76%-100% target lesion shrinkage, respectively. No new safety findings were observed with longer follow-up. CONCLUSIONS: Brigatinib (180 mg once daily with lead-in) continues to demonstrate robust PFS, long iPFS and duration of intracranial response, and high intracranial objective response rate in crizotinib-refractory patients. Depth of response may be an important end point to capture in future targeted therapy trials.
引用
- Huber RM, Hansen KH, Paz-Ares Rodríguez L, et al. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. J Thorac Oncol. 2019. PMID: 31756496. doi:10.1016/j.jtho.2019.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。